TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06971731: A Phase 3, Double-Blind, Randomized, Two-Period, Multicenter, Placebo-Controlled, Efficacy and Safety Study of JNT-517 for the Treatment of Participants With Phenylketonuria

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 120 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$5,987,288

Rescue Site Savings

+$3,960,096

Unlock Full NCT06971731 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06971731 Rescue Dossier →